347185-68-6

Basic information

• Product Name: Carbamic acid, [(1R,3S)-3-(hydroxymethyl)cyclopentyl]-, 1,1-dimethylethyl
• Synonyms: Carbamic acid, [(1R,3S)-3-(hydroxymethyl)cyclopentyl]-, 1,1-dimethylethyl;tert-Butyl [(1R,3S)-3-(hydroxymethyl)cyclopentyl]carbamate
• CAS NO: 347185-68-6
• Molecular Formula: C₁₁H₂₁NO₃
• Molecular Weight: 215.28934
• Product Categories: N-BOC
• Mol File: 347185-68-6.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Carbamic acid, [(1R,3S)-3-(hydroxymethyl)cyclopentyl]-, 1,1-dimethylethyl(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, [(1R,3S)-3-(hydroxymethyl)cyclopentyl]-, 1,1-dimethylethyl(347185-68-6)
• EPA Substance Registry System: Carbamic acid, [(1R,3S)-3-(hydroxymethyl)cyclopentyl]-, 1,1-dimethylethyl(347185-68-6)

Safety Data

• Hazardous Substances Data: 347185-68-6(Hazardous Substances Data)

Upstream product

• 693245-53-3 tert-butyl (1R,4S)-3-oxo-2-azabicyclo[2.2.1]heptane-2-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 71830-07-4 (1S,3R)-3-aminocyclopentanecarboxylic acid 
• 130931-83-8 (1S,4R)-2-azabicyclo[2,2,1]hept-5-en-3-one 
• 153011-43-9 (1S,cis)-tert-butyl N-[4-(hydroxymethyl)-2-cyclopenten-1-yl]carbamate 
• 261165-05-3 (1S,3R)-3-(tert-butoxycarbonylamino)cyclopentanecarboxylic acid 
• 108999-93-5 (1SR,4RS)-4-[(tert-butyloxycarbonyl)amino]cyclopent-2-enecarboxylic acid 
• 49805-30-3 racemic 2-azabicyclo[2.2.1]hept-5-en-3-one 
• 200002-41-1 (-)-[(1R,4S)-tert-butyl 3-oxo-2-azabicyclo(2.2.1)hept-5-ene-2-carboxylate] 
• 134003-02-4 (-)-2-Azabicyclo<2.2.1>heptan-3-one 

Downstream Products

• 862701-90-4 N₁-boc-(3S,1R)-3-(4-cyano-3-fluorophenoxymethyl)cyclopentan-1-amine 
• 862701-74-4 N₁-boc-(3S,1R)-3-(4-nitrophenoxymethyl)cyclopentan-1-amine 
• 347185-69-7 ((1S,3R)-3-(tert-butoxycarbonylamino)cyclopentyl)methyl 4-methylbenzenesulfonate 
• 1261254-08-3 tert-butyl (1R,3S)-3-((4-benzylpiperidin-1-yl)methyl)cyclopentylcarbamate 
• 1233561-11-9 tert-butyl {(1R,3S)-3-[(benzyloxy)methyl]cyclopentyl}carbamate 
• 1233561-12-0 (1R,3S)-3-[(benzyloxy)methyl]cyclopentanamine hydrochloride 
• 1110772-11-6 ((1S,3R)-3-aminocyclopentyl)methanol 
• 1263371-89-6 ((1S,3R)-3-(5'-chloro-6-(3-fluorobenzylamino)-2,4'-bipyridin-2'-yl-amino)cyclopentyl)methanol 
• 1263375-29-6 (1S,3R)-3-(5'-chloro-6-(3-fluorobenzylamino)-2,4'-bipyridin-2'-yl-amino)cyclopentanecarbaldehyde 
• 862701-86-8 N₁-boc-(3S,1R)-3-(4-cyanophenoxymethyl)cyclopentan-1-amine 
• 551964-52-4 3-(3-tert-butoxycarbonylamino-cyclopentyl)-3-[tert-butoxycarbonyl-(4-methoxy-benzyl)-amino]-propionic acid tert-butyl ester 
• 551964-51-3 3-(3-tert-butoxycarbonylamino-cyclopentyl)-3-(4-methoxy-benzylamino)-propionic acid tert-butyl ester 
• 551964-49-9 ((1R,3S)-3-formyl-cyclopentyl)-carbamic acid tert-butyl ester 

Relevant articles and documents

PYRAZOLYL COMPOUNDS AND METHODS OF USE THEREOF

Compounds having activity as chemotherapeutic agents are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, stereoisomer, isotopic form or prodrug thereof, wherein R1a, R1b, R1c, R1d, L, and are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods for treating cancer (e.g., hematological cancers) are also provided.

PYRIMIDINE BIARYL AMINE COMPOUNDS AND THEIR USES

The present invention provides a pyrimidine compound of formula (I): wherein one of X and Y but not both is N, and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tantomers, diastereomers, deuterated versions, or racemates thereof. These compounds inhibit the activity of CDK9 and are thus useful as pharmaceuticals. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds of Formula I and isomers thereof, and pharmaceutical compositions comprising such compounds

DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF AS HIF ACTIVATORS

The present invention relates to novel substituted dihydropyrazolone derivatives, to their preparation and to their therapeutic use as activators of the transcription factor HIF.